ESMO25: On getting ahead of cancer, with J&J's Henar Hevia & Carolyn Sousa

T-cell-redirecting bispecific antibodies have emerged as one of the most promising avenues within tumour immunotherapy.

In an interview at ESMO 2025 with Johnson & Johnson’s Henar Hevia, senior director and EMEA therapeutic area lead in oncology, together with Carolyn Sousa, regional commercial strategy lead, EMEA, in solid tumour oncology, pharmaphorum asked these two experts about the company’s breaking clinical data on pasritamig – an investigational, first-in-class bispecific T-cell-redirecting antibody – in prostate cancer.

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data means for patients and physicians, and the importance of getting ahead of cancer, as well as Johnson & Johnson’s work in head and neck cancer.

Watch this and other conversations from onsite in Berlin for ESMO 2025 here.